Sweden's Medivir in partner talks for drug candidate MIV-802

Swedish pharmaceutical company Medivir is in ongoing discussions to license hepatitis C drug candidate MIV-802 to another firm, it said on Thursday. In December Medivir said MIV-802 had been selected as a candidate drug and entered non-clinical development. "It is almost unlikely that we will take it trough a phase-II," Chief Executive Niklas Prager told a meeting of investors, analysts and media and added that it is more likely that the company will sign a partner agreement for the drug candidate's further development. Medivir has the ambition to deliver on average one drug candidate every year, and to maintain an average of one project in the first phase of clinical development.



via Health News Headlines - Yahoo News http://ift.tt/1OAD4AD